Lizzy Smyth
@LizzySmyth1
Medical Oncologist. Cancer Clinical Trials @OxfordCancer #GIcancer #ESMO #EORTC
📖 The ESMO Targeted Anticancer Therapies Asia Congress 2025 resources are now available on OncologyPro. 🔗 ow.ly/Viz850WsBP8 📚Explore cutting-edge discoveries and expert-led discussions from #ESMOTATAsia25 - where the science of early-phase oncology meets innovation.…
Very pleased to be part of this important discussion on young onset GICancer at #ESMOGI25. Let's raise awareness!
Very nice summary of an important topic discussed during the @myESMO #ESMOGI25 #PressBriefing by @LiamDJournalist Early onset and increasing incidence of cancer - “Not to scare, but to inform” 😉 👉medicalnewsinsider.substack.com/p/bowel-cancer…
What a difference a day makes.. First ever mid-typhoon lecture ⛈️🌧️🌀 #Wipha Thanks to our wonderful #ESMOTATAsia25 hosts and @myESMO for looking after us with ✈️ cancelled. Stay safe ☔ everyone!
Rain, hail or typhoon🌧️🌪️ - D3 #ESMOTATAsia25 commenced with Prof Elizabeth Smyth giving an overlook on new ADC constructs-payload innovation; bispecific ADCs; smaller format delivery systems to incr therap window & reduce tox @myESMO 🇭🇰
It's not just about the food....but really enjoying #ESMOTATAsia25! Thank you @myESMO for the invitation to this excellent inaugural meeting celebrating the success of #clinicaltrials for patients with #cancer in #Asia.
🎧 Another @myESMO Upper GI podcast! We break down key #ASCO25 updates in #EsophagealCancer & #GastricCancer: ✔️ CheckMate 577 ✔️ Matterhorn ✔️ DESTINY-Gastric04 ✔️ SATRi-cel (CAR-T!) With @LizzySmyth1, Sylvie Lorenzen & @ThAlcin 🎙 Listen now: open.spotify.com/episode/65JSJu… #GIonc
👉 ESMO Living Guidelines on Localised Rectal Cancer: New title in the library with all recommendations and algorithms from the published Guideline in an interactive format. #ESMOGuidelines 🔗 ow.ly/PggR50WkRKH @erikamartin3lli
📢 #HealthierEurope. Better access. ESMO welcomes the @EU_Commission’s Life Sciences Strategy - a bold step to reform #IVDR & support clinical innovation. Let’s ensure Europe leads in life sciences & #PatientsCare. @jeanyvesblay 🔗ow.ly/Pvgr50WkTyU
Loving this ladies of #GIOnc 📷 at #ESMOGI25! Excellent faculty and great meeting! Thank you @myESMO 🙏
Wonderful faculty dinner last night! 🙏🏻 @myESMO @KarynAGoodman @Betzabe100 @ben_irit @RachelRiechelm2 @LizzySmyth1 @MacarullaTeresa @Juanmaoconnor and so many others! #ESMOGI25 #ESMOAmbassadors #cancer #CancerResearch
🚨 Updates from #ESMOGI25 on new targeted therapies in GE cancer: 🔹 Zanidatamab (Ph2): ORR >80%, promising PFS 🔹 HER2-low: would non-ADC ChT result in same? 🔹 Claudin18.2 & MET-targeting gaining traction 🔹 FGFR2b ADCs in pipeline 🔹 ADC + IO: the new combo frontier? HER2 we…
BiTEs & BiKEs, TRiTEs & TRiKEs by #elisafontana excellent talk for those lost in this very quickly evolving field 👇 @myESMO #ESMOAmbassadors #ESMOGI25 @OncoAlert
Thank you to all the panelist for joining me during this #PressBriefing at @myESMO #ESMOGI25 Highlighting the main hot topics of the conference of its wider spread to the public 🛟Prevention 💊New therapies 🫂Relevance of quality of life ⌚️Digital oncology #ESMOAmbassadors
🙏 Thank you to everyone who voted in the recent #ESMO election 🗳️ I'm pleased to announce that I was elected as Director of Education and I am looking forward to working on behalf of all @myesmo members on a globally 🌏 inclusive education programme! rb.gy/efu7cq
👏👏 nice biomarker work from @KoheiShitara and NCCHE team (again!) FGFR2b overexpressing gastro- esophageal cancer is a distinct and targetable subgroup 🎯 FGFR2b 💊 bemaritizumab 👀 FORTITUDE 101 and 102 trials hopefully to report this year!
Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers @ESMO_Open @myESMO. The results of bemarituzumab phase 3 studies are awaited.@OncoAlert @oncodaily sciencedirect.com/science/articl…
The new ESMO Living Guideline on RCC
👉 ESMO Living Guidelines on Renal Cell Carcinoma v1.1: New title with updated recommendations and algorithms from the published Guideline in an interactive format. 🔗 ow.ly/X3AU50W8PEi
📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global @myESMO community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️
Gastric cancer @TheLancet doi.org/10.1016/S0140-… 👏Excellent and comprehensive summary from screening to targeted therapies by @sundar__raghav @LizzySmyth1 @YJanjigianMD @KoheiShitara @HannekevanLaar1 @myESMO
The #OncoAlertTopTweet 🚨Day THREE of #ASCO25 Post by @LizzySmyth1 MATTERHORN - first ever randomised trial to show a significant benefit for ICI (or any targeted therapy) in operable gastroesophageal cancer. ~10% ⬆️ EFS at 2y #OncoAlertAF @nataliagandur @acampsmalea…
#ASCO25 ⛰️MATTERHORN - first ever randomised trial to show a significant benefit for ICI (or any targeted therapy) in operable gastroesophageal cancer. ~10% ⬆️ EFS at 2y EFS is important in a disease where metastases cause real morbidity Happy for my patients!
#ASCO25 Karin Jordin is my wonderful co-candidate in the #ESMO elections. We would both like to remind all @myESMO members to #vote! #friends #solidarity #education
#ASCO25 Many new drugs ➡️ welcome but marginal gains. 💰 Cost + ☣️ toxicity Exercise ➡️ marginal cost + negligible toxicity ✅ Evidence based intervention should be added to standard treatment recommendations No need to wait for regulatory approval! Do it now!
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:…